#$%^&*AU2013201915A120130411.pdf#####Abstract The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) a pyrimidylaminobenzamide compound to 5 pharmaceutical compositions comprising said combinations and to a method of treating a warm-blooded animal having leukemia, especially chronic myelogenous leukemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Btk kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting 10 simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abi tyrosine kinase activity, in combination with a pyrimidylaminobenzamide compound, in particular 4-Methyl3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1 H-imidazol--yl)-3(trifluoromethyl)phenyl] benzamide.
